Taiwo Adesoye1, Heather B Neuman1,2, Lee G Wilke2, Jessica R Schumacher1, Jennifer Steiman2, Caprice C Greenberg3,4. 1. Wisconsin Surgical Outcomes Research (WiSOR) Program, Department of Surgery, University of Wisconsin Hospitals and Clinics, Madison, WI, USA. 2. Division of Surgical Oncology, Department of Surgery, University of Wisconsin Hospitals and Clinics, Madison, WI, USA. 3. Wisconsin Surgical Outcomes Research (WiSOR) Program, Department of Surgery, University of Wisconsin Hospitals and Clinics, Madison, WI, USA. greenberg@surgery.wisc.edu. 4. Division of Surgical Oncology, Department of Surgery, University of Wisconsin Hospitals and Clinics, Madison, WI, USA. greenberg@surgery.wisc.edu.
Abstract
INTRODUCTION: National Comprehensive Cancer Network (NCCN) guidelines recommend wide excision without axillary staging to treat phyllodes tumors of the breast. Without prospective trials to guide management, NCCN also recommends consideration of radiation therapy (XRT). We describe current patterns of care for the multidisciplinary management of phyllodes tumors. METHODS: Using Surveillance, Epidemiology, and End Results Program (SEER) data, we identified women diagnosed with phyllodes tumors between 2000 and 2012 who underwent surgical therapy. Trends in breast-conserving surgery (BCS), nodal sampling, and XRT were assessed using the Cochrane-Armitage test. Multivariable logistic regression was used to identify factors associated with treatment. RESULTS: Of 1238 patients, 56.9 % underwent BCS and 23.6 % underwent nodal sampling (10.5 % after BCS vs. 40.9 % after mastectomy). After surgery, 15.4 % received adjuvant XRT (BCS 12.9 %, and mastectomy 18.8 %). XRT utilization increased significantly over the study period (BCS, p = < 0.0001; mastectomy, p = 0.0003), while nodal sampling did not change significantly. Women were more likely to receive mastectomy if they were older or had larger tumors. Nodal sampling was also associated with older age, larger tumor size, and receipt of mastectomy. Receipt of XRT was associated with later year of diagnosis, larger tumors, and nodal assessment. CONCLUSION: Over time, an increasing number of women received XRT after surgical management of phyllodes tumor, and one in four women underwent nodal sampling. While some of this practice can be attributed to concern about more advanced disease in the absence of strong data, there may be an educational gap regarding current guidelines and appropriate management.
INTRODUCTION: National Comprehensive Cancer Network (NCCN) guidelines recommend wide excision without axillary staging to treat phyllodes tumors of the breast. Without prospective trials to guide management, NCCN also recommends consideration of radiation therapy (XRT). We describe current patterns of care for the multidisciplinary management of phyllodes tumors. METHODS: Using Surveillance, Epidemiology, and End Results Program (SEER) data, we identified women diagnosed with phyllodes tumors between 2000 and 2012 who underwent surgical therapy. Trends in breast-conserving surgery (BCS), nodal sampling, and XRT were assessed using the Cochrane-Armitage test. Multivariable logistic regression was used to identify factors associated with treatment. RESULTS: Of 1238 patients, 56.9 % underwent BCS and 23.6 % underwent nodal sampling (10.5 % after BCS vs. 40.9 % after mastectomy). After surgery, 15.4 % received adjuvant XRT (BCS 12.9 %, and mastectomy 18.8 %). XRT utilization increased significantly over the study period (BCS, p = < 0.0001; mastectomy, p = 0.0003), while nodal sampling did not change significantly. Women were more likely to receive mastectomy if they were older or had larger tumors. Nodal sampling was also associated with older age, larger tumor size, and receipt of mastectomy. Receipt of XRT was associated with later year of diagnosis, larger tumors, and nodal assessment. CONCLUSION: Over time, an increasing number of women received XRT after surgical management of phyllodes tumor, and one in four women underwent nodal sampling. While some of this practice can be attributed to concern about more advanced disease in the absence of strong data, there may be an educational gap regarding current guidelines and appropriate management.
Authors: O Kenneth Macdonald; Christopher M Lee; Jonathan D Tward; Craig D Chappel; David K Gaffney Journal: Cancer Date: 2006-11-01 Impact factor: 6.860
Authors: B Salvadori; F Cusumano; R Del Bo; V Delledonne; M Grassi; D Rovini; R Saccozzi; S Andreola; C Clemente Journal: Cancer Date: 1989-06-15 Impact factor: 6.860
Authors: Andrea V Barrio; Bradly D Clark; Jessica I Goldberg; Laura W Hoque; Stephanie F Bernik; Laurie W Flynn; Barbara Susnik; Dilip Giri; Kristen Polo; Sujata Patil; Kimberly J Van Zee Journal: Ann Surg Oncol Date: 2007-06-12 Impact factor: 5.344
Authors: Jennifer L Gnerlich; Richelle T Williams; Katherine Yao; Nora Jaskowiak; Swati A Kulkarni Journal: Ann Surg Oncol Date: 2013-12-04 Impact factor: 5.344
Authors: Lily Gutnik; Yi Ren; Samantha M Thomas; Jennifer K Plichta; Rachel A Greenup; Oluwadamilola M Fayanju; E Shelley Hwang; Laura H Rosenberger Journal: J Surg Oncol Date: 2022-02-18 Impact factor: 3.454